DRUG · Unmapped registry intervention
Tenofovir + emtricitabine + raltegravir.
Find medicine records ·
Find other trials using this name
Clinical trial
The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
NCT00641641
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedThe Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HIV Infectionverified · MONDO: HIV infectious disease
Interventions
Sponsors & collaborators
Kirby Institutelead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00641641 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.